Meeting
2022 ASCO Quality Care Symposium
Developing a standardized approach to prevention and outpatient management of febrile neutropenia.
Authors
Andrea Crespo
Ontario Health (Cancer Care Ontario), Toronto, ON, Canada
Andrea Crespo, Daniela Gallo-Hershberg, Katherine Enright, Leta Marie Forbes, Kathy Vu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Palliative and Supportive Care,Technology and Innovation in Quality of Care,Quality, Safety, and Implementation Science
Sub Track
Toxicity Prevention, Assessment, and Management
Citation
J Clin Oncol 40, 2022 (suppl 28; abstr 234)
DOI
10.1200/JCO.2022.40.28_suppl.234
Abstract #
234
Poster Bd #
C1
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Quality Care Symposium
Growth factor use in patients with breast cancer treated with docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) regimen: Cost implications in a safety-net system.
First Author: Sarah Kashanian
Poster
2022 ASCO Annual Meeting
Real-world effectiveness of prophylactic granulocyte colony-stimulating factor (G-CSF) early (week 1) and late (weeks 2-3) in the cycle for the prevention of febrile neutropenia (FN) among patients (pts) with breast cancer (BC) after high FN–risk chemotherapy (chemo).
First Author: Douglas W. Blayney
Poster
2019 ASCO Annual Meeting
Clinical impact of neutropenia and febrile neutropenia in mCRC pts treated with FOLFOXIRI/bevacizumab (bev): A pooled analysis of TRIBE and TRIBE2 studies.
First Author: Daniele Rossini
Poster
2018 ASCO Quality Care Symposium
Optimizing the use of trimethoprim-sulfamethoxazole for prevention of PCP and opportunistic infections in allogeneic hematopoietic cell transplant recipients.
First Author: Emily Baneman